A Common Functional Ability Score for Young People with Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis

Arthritis Care Res (Hoboken).

Brunner HI, Chen C, Bovis F, De Benedetti F, Espada G, Joos R, Akikusa J, Chaitow J, Boteanu AL, Kimura Y, Rietschel C, Siri D, Smolewska E, Schmeling H, Brown DE, Martini A, Lovell DJ, Huang B, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)

doi: 10.1002/acr.24384.

Juvenile Idiopathic Arthritis

Long-term outcomes in juvenile idiopathic arthritis: 18 years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis (JIA) cohort

Arthritis Care Res (Hoboken).

Glerup M, Rypdal V, Arnstad ED, Ekelund M, Peltoniemi S, Aalto K, Rygg M, Toftedal P, Nielsen S, Fasth A, Berntson L, Nordal E, Herlin T, Nordic Study Group of Pediatric Rheumatology (NoSPeR)

doi: 10.1002/acr.23853.

Juvenile Idiopathic Arthritis

Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom

Rheumatology (Oxford).

Kearsley-Fleet L, Sampath S, McCann LJ, Baildam E, Beresford MW, Davies R, De Cock D, Foster HE, Southwood TR, Thomson W, Hyrich KL

doi: 10.1093/rheumatology

Juvenile Idiopathic Arthritis

Genomic risk scores for juvenile idiopathic arthritis and its subtypes

Ann Rheum Dis.

Cánovas R, Cobb J, Brozynska M, Bowes J, Li YR, Smith SL, Hakonarson H, Thomson W, Ellis JA, Abraham G, Munro JE, Inouye M

doi: 10.1136/annrheumdis-2020-217421.

Juvenile Idiopathic ArthritisSystemic Sclerosis

CAPTURE-JIA: a consensus-derived core dataset to improve clinical care for children and young people with juvenile idiopathic arthritis

Rheumatology (Oxford).

McErlane F, Armitt G, Cobb J, Bailey K, Cleary G, Douglas S, Lunt L, Rashid A, Sampath S, Shoop-Worrall S, Smith N, Foster H, Thomson W

doi: 10.1093/rheumatology/

Juvenile Idiopathic Arthritis

Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study

Rheumatology (Oxford).

Heiligenhaus A, Klotsche J, Tappeiner C, Sengler C, Niewerth M, Liedmann I, Hoeft S, Walscheid K, Lavric M, Foell D, Minden K

doi: 10.1093/rheumatology/key406.

Further Publications Rheumatology

Consensus-driven conceptual development of a standardized whole body-MRI scoring system for assessment of disease activity in juvenile idiopathic arthritis: MRI in JIA OMERACT working group

Semin Arthritis Rheum

Panwar J, Tolend M, Redd B, Srinivasalu H, Colbert RA, Akikusa J, Appenzeller S, Carrino JA, Herregods N, Jans L, Highmore K, von Kalle T, Kirkhus E, Rumsey DG, Jaremko JL, Clemente IEJ, van Rossum MA, Stimec J, Tse SM, Twilt M, Tzaribachev N, Sudol-Szopinska I, Meyers AB, Doria AS

doi: 10.1016/j.semarthrit.2021.07.017

Juvenile Idiopathic Arthritis

Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis

N Engl J Med.

Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, Hardwick B, Hickey H, Hughes D, Woo P, Benton D, Edelsten C, Beresford MW; SYCAMORE Study Group

doi: 10.1056/NEJMoa1614160.

Juvenile Idiopathic Arthritis

Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis

Ann Rheum Dis.

Minoia F, Bovis F, Davì S, Horne A, Fischbach M, Frosch M, Huber A, Jelusic M, Sawhney S, McCurdy DK, Silva CA, Rigante D, Unsal E, Ruperto N, Martini A, Cron RQ, Ravelli A, Pediatric Rheumatology International Trials Organization, the Childhood Arthritis & Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group and the Histiocyte Society.

doi: 10.1136/annrheumdis-

Related content

Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis

Long-term outcomes in juvenile idiopathic arthritis: 18 years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis (JIA) cohort

Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom

Genomic risk scores for juvenile idiopathic arthritis and its subtypes

CAPTURE-JIA: a consensus-derived core dataset to improve clinical care for children and young people with juvenile idiopathic arthritis

Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study

Consensus-driven conceptual development of a standardized whole body-MRI scoring system for assessment of disease activity in juvenile idiopathic arthritis: MRI in JIA OMERACT working group

Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis

Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis